1). Montorsi F, Burnett AL. Erectile dysfunction after radical prostatectomy. BJU Int. 2004; 93:1–2.
Article
2). Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology. 2000; 55:58–61.
Article
3). Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol. 2008; 18:613–20.
Article
4). Mulhall JP, Slovick R, Hotaling J, Aviv N, Valenzuela R, Waters WB, et al. Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J Urol. 2002; 167:1371–5.
Article
5). User HM, Hairston JH, Zelner DJ, McKenna KE, McVary KT. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol. 2003; 169:1175–9.
Article
6). Ferrini MG, Kovanecz I, Sanchez S, Umeh C, Rajfer J, Gonzalez-Cadavid NF. Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat. J Sex Med. 2009; 6:415–28.
Article
7). Mulhall JP, Graydon RJ. The hemodynamics of erectile dysfunction following nerve-sparing radical retropubic prostatectomy. Int J Impot Res. 1996; 8:91–4.
8). Mulhall JP, Müller A, Donohue JF, Mullerad M, Kobylarz K, Paduch DA, et al. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. J Sex Med. 2008; 5:1126–36.
Article
9). Fall PA, Izikki M, Tu L, Swieb S, Giuliano F, Bernabe J, et al. Apoptosis and effects of intracavernous bone marrow cell injection in a rat model of postprostatectomy erectile dysfunction. Eur Urol. 2009; 56:716–25.
Article
10). Gratzke C, Strong TD, Gebska MA, Champion HC, Stief CG, Burnett AL, et al. Activated RhoA/Rho kinase impairs erectile function after cavernous nerve injury in rats. J Urol. 2010; 184:2197–204.
Article
11). Cho MC, Park K, Chai JS, Lee SH, Kim SW, Paick JS. Involvement of sphingosine-1-phosphate/RhoA/Rho-kinase signaling pathway in corporal fibrosis following cavernous nerve injury in male rats. J Sex Med. 2011; 8:712–21.
Article
12). Jin HR, Chung YG, Kim WJ, Zhang LW, Piao S, Tuvshintur B, et al. A mouse model of cavernous nerve injury-induced erectile dysfunction: functional and morphological characterization of the corpus cavernosum. J Sex Med. 2010; 7:3351–64.
Article
13). Park K, Lee DG, Kim SW, Paick JS. Dimethylarginine dimethylaminohydrolase in rat penile tissue: reduced enzyme activity is responsible for erectile dysfunction in a rat model of atherosclerosis. Int J Impot Res. 2009; 21:228–34.
Article
14). Park K, Ryu KS, Li WJ, Kim SW, Paick JS. Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction. Eur Urol. 2008; 53:1282–8.
Article
15). Li WJ, Park K, Paick JS, Kim SW. Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats. J Sex Med. 2011; 8:400–10.
Article
16). Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by longterm sildenafil treatment: role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol. 2005; 68:226–32.
Article
17). Mullerad M, Donohue JF, Li PS, Scardino PT, Mulhall JP. Functional sequelae of cavernous nerve injury in the rat: is there model dependency. J Sex Med. 2006; 3:77–83.
Article
18). Kim HJ, Kim HY, Kim SY, Lee SH, Lee WK, Yang DY. Spontaneous recovery of cavernous nerve crush injury. Korean J Urol. 2011; 52:560–5.
Article
19). Lagoda G, Jin L, Lehrfeld TJ, Liu T, Burnett AL. FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. J Sex Med. 2007; 4:908–16.
Article
20). Zhou H, Zhang KX, Li YJ, Guo BY, Wang M, Wang M. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses high glucose-induced proliferation and collagen synthesis in rat cardiac fibroblasts. Clin Exp Pharmacol Physiol. 2011; 38:387–94.
21). Washida N, Wakino S, Tonozuka Y, Homma K, Tokuyama H, Hara Y, et al. Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis. Nephrol Dial Transplant. 2011; 26:2770–9.
Article
22). Takeda Y, Nishikimi T, Akimoto K, Matsuoka H, Ishimitsu T. Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction. Hypertens Res. 2010; 33:965–73.
Article
23). Satoh S, Yamaguchi T, Hitomi A, Sato N, Shiraiwa K, Ikegaki I, et al. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol. 2002; 455:169–74.
Article
24). Zhou H, Li YJ, Wang M, Zhang LH, Guo BY, Zhao ZS, et al. Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes. Acta Pharmacol Sin. 2011; 32:999–1008.
Article
25). Moriyama T, Nagatoya K. The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis. Drug News Perspect. 2004; 17:29–34.
Article
26). Musicki B, Burnett AL. eNOS function and dysfunction in the penis. Exp Biol Med (Maywood). 2006; 231:154–65.
Article
27). Jung GW, Kwak JY, Yoon S, Yoon JH, Lue TF. IGF-I and TGF-beta2 have a key role on regeneration of nitric oxide synthase (NOS)-containing nerves after cavernous neurotomy in rats. Int J Impot Res. 1999; 11:247–59.
28). Burnett AL, Becker RE. Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury. J Urol. 2004; 171:495–500.
Article